The evaluation of honey bee venom potential therapeutic value on gonadotropin-induced ovarian hyperstimulation syndrome model rats

Abstract Ovarian hyperstimulation syndrome (OHSS) mostly occurs in undergoing gonadotropin therapy women sensitive to endogenous gonadotropins. Honey bee venom (HBV) contains biologically active components that has pharmaceutical properties. This study was designed to assess the possibility of HBV application as an anti-inflammatory and anti-angiopathy therapeutic agent to suppress main inflammatory mediators in OHSS. OHSS induced by Pregnant Mare’s Serum Gonadotropin) PMSG) and hCG intraperitoneal in immature female Wistar rats. OHSS induction followed by intraperitoneal injection of HBV and metformin for 10 consecutive days;. At the end of the treatment period, metabolic parameters as well as ovarian expression of IL-6, COX2, and VEGF proteins were evaluated. This data showed that the OHSS+HBV group had a significant reduction in peritoneal and ovarian vascular permeability compared to the OHSS group. The ovarian expression of COX2, IL-6 and VEGF proteins in group OHSS+HBV.. The results of this study showed that HBV can affect the inflammatory feature of OHSS by reducing the angiogenesis factors.